Pedro photo.jpg

Pedro Lichtinger, Chairman & CEO

An industry executive with a 37-year career in biotechnology and a proven track record of developing turnaround and financing strategies, executing strategic alliances, and building commercial and R&D capabilities. Former President and CEO of Asterias Biotherapeutics and Optimer Pharmaceuticals with 16 years experience at Pfizer Inc as President of Global Primary Care and President of Europe. 
He currently serves on Board of Directors for Gemphire Therapeutics and Sanfer de Mexico and sits on the Advisory Board of Zero Gravity.   He holds an MBA degree from Wharton School of Business and an engineering degree from the National University of Mexico.



Dr. Oliver’s experience spans 12 years in academia and 24 years in both the public and private sectors of the biotechnology/pharmaceutical industry and contract research organizations. He has served in numerous roles in clinical development operations including Chief Operating Officer, SVP Clinical Research and Regulatory Affairs, and Chief Science Officer, and Medical Officer. Over his career he has successfully managed large cross-functional project teams with internal staff and oversaw CRO vendors. Dr. Oliver has significant FDA iexperience with both the Drug and Biologic divisions having prepared more than 50 INDs and participated in seven successful NDA submissions for U.S./Global pharmaceutical companies. In his tenure with public and private biotechnology companies, he participated in several series of successful fund raisings. In addition, Dr Oliver has served in licensing negotiations and out-licensing of several oncology assets.

Chris Chipman, Chief Financial Officer

Mr. Chipman is a managing member of Chipman & Chipman, LLC, providing assistance to public companies with the preparation of periodic reports required to be filed with the SEC and compliance with Section 404 of the Sarbanes Oxley Act of 2002. He was Chief Financial Officer and Secretary of Capital Gold Corporation from 2006 to June 2011. During his tenure, Capital Gold Corporation’s market capitalization increased from $40 million to $420 million. Mr. Chipman successfully negotiated and facilitated the $420 million sale of Capital Gold Corporation to AuRico Gold, Inc. representing a 67% premium over its market price to its shareholders. He has also held senior accounting and financial analyst roles with Grant Thornton LLP and GlaxoSmithKline, and was an Audit Examiner for Wachovia Corporation. He received a B.A. in Economics from Ursinus College and is a Certified Public Accountant. He is a member of the American and Pennsylvania Institute of Certified Public Accountants.

andy photo.jpg

Andy rensink, Chief Manufacturing OFFICER

Executive bringing over 30 years of operational experience including 13 years experience in transdermal development and manufacturing. Former President and COO of Tapemark, leading development, strategy implementation for pharmaceutical CDMO developing and manufacturing Transdermal Patches and Oral Thin Film products. Currently sits on the Board of Advisors for Hydra-Flex chemical dispensing systems. Holds a Masters in Engineering  from Marquette University, BSME from University of Wisconsin and completed the GE Manufacturing Management Program.



Known for implementation in the biotech sector, she has spent most of her career creating and validating biotech companies. Previously in New Product Development at Aequus Pharmaceuticals, a transdermal reformulation company. Holds a Master of Management from the University of British Columbia and a Bachelor of Health Science and Biology from Western University
Based in Vancouver, Canada for ChemioCare Inc


Mark Robbins, Regulatory Advisor

Biopharmaceutical drug development professional with over 30 years of drug development and commercialization experience in both start-up and fully integrated pharmaceutical/biotechnology companies. Dr. Robbins is President of Kodiak Strategic Consultants. Previously served in senior management positions at Upsher-Smith Laboratories, Certus International, and Mallinckrodt. He has implemented regulatory/clinical strategies leading to many successful NDA/BLA approvals. He received his B.S. degree in Biochemistry from UCLA, his Ph.D. in Pharmacology from the University of Minnesota Medical School, and his J.D. magna cum laude from Saint Louis University.

Hemal Shah, Health Economics & Outcomes Advisor

Executive bringing over 20 years of experience in health economics & outcomes research (HEOR), real world evidence generation, pricing, market access, value demonstration and health policy. Former Senior Vice President, Medical Affairs, Healthcare Quality, Policy and Outcomes at Optimer Pharmaceuticals and Executive Director of HEOR at Boehringer Ingelheim. She holds a Doctor of Pharmacy from The State University of New Jersey, a BSc. in Pharmacy and a BSc. in Molecular & Cell Biology from University of Connecticut and has completed a post-doctoral fellowship in outcomes research at Geisinger Health System/Novartis.